Biotech ETFs have been the focus of many investors this week after Valeant Pharmaceuticals Intl. Inc. (NYSE: VRX) shares dropped more than 46% last week. One biotech ETF with Valeant as a holding slumped 8.4% in the past three months, as VRX stock continues to fall. Since August, shares of the drug giant - dubbed by short seller Citron Research as "pharma's Enron" - have plunged 56%. Year to date, VRX stock is down 22.4%... Tags: biotech ETF , biotech etfs , biotech etfs 2015 , biotech stocks , biotech stocks 2015 , biotechs , ETFs Article , NYSE: VRX , Valeant Pharmaceuticals , Valeant stock , Valeant stock price , VRX stock , VRX stock price To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post How Biotech ETFs Have Performed During the Valeant Stock Crash (NYSE: VRX) appeared first on Money Morning - We Make Investing Profitable .